In‐patient discharge rates for the irritable bowel syndrome – an analysis of national trends in the United States from 1997 to 2010

Sethi, Saurabh; Wadhwa, Vaibhav; LeClair, John; Mikami, Sage; Jones, Michael; Sethi, Nidhi; Brown, Alphonso; Lembo, Anthony

doi:10.1111/apt.12532

Cited by 15 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2013 NIS contains discharge data from over 4000 hospitals in 44 States, totaling about 8 million records. This large database is an excellent representative sample of the general United States population, representing more than 95 percent of the United States population and useful for analyzing health care utilization, access, charges, quality, and outcomes[7,8]. The NIS database provides only administrative data for analysis.…”

Section: Methodsmentioning

confidence: 99%

Healthcare utilization and costs associated with gastroparesis

Wadhwa¹,

Mehta²,

Jobanputra³

et al. 2017

WJG

101

View full text Add to dashboard Cite

AIMTo use a national database of United States hospitals to evaluate the incidence and costs of hospital admissions associated with gastroparesis.METHODSWe analyzed the National Inpatient Sample Database (NIS) for all patients in whom gastroparesis (ICD-9 code: 536.3) was the principal discharge diagnosis during the period, 1997-2013. The NIS is the largest publicly available all-payer inpatient care database in the United States. It contains data from approximately eight million hospital stays each year. The statistical significance of the difference in the number of hospital discharges, length of stay and hospital costs over the study period was determined by regression analysis.RESULTSIn 1997, there were 3978 admissions with a principal discharge diagnosis of gastroparesis as compared to 16460 in 2013 (P < 0.01). The mean length of stay for gastroparesis decreased by 20 % between 1997 and 2013 from 6.4 d to 5.1 d (P < 0.001). However, during this period the mean hospital charges increased significantly by 159 % from $13350 (after inflation adjustment) per patient in 1997 to $34585 per patient in 2013 (P < 0.001). The aggregate charges (i.e., “national bill”) for gastroparesis increased exponentially by 1026 % from $50456642 ± 4662620 in 1997 to $568417666 ± 22374060 in 2013 (P < 0.001). The percentage of national bill for gastroparesis discharges (national bill for gastroparesis/total national bill) has also increased over the last 16 years (0.0013% in 1997 vs 0.004% in 2013). During the study period, women had a higher frequency of gastroparesis discharges when compared to men (1.39/10000 vs 0.9/10000 in 1997 and 5.8/10000 vs 3/10000 in 2013). There was a 6-fold increase in the discharge diagnosis of gastroparesis amongst type 1 DM and 3.7-fold increase amongst type 2 DM patients over the study period (P < 0.001).CONCLUSIONThe number of inpatient admissions for gastroparesis and associated costs have increased significantly over the last 16 years. Inpatient costs associated with gastroparesis contribute significantly to the national healthcare bill. Further research on cost-effective evaluation and management of gastroparesis is required.

show abstract

Section: Methodsmentioning

confidence: 99%

Healthcare utilization and costs associated with gastroparesis

Wadhwa¹,

Mehta²,

Jobanputra³

et al. 2017

WJG

101

View full text Add to dashboard Cite

show abstract

“…The 2012 NIS contains discharge data from > 4000 hospitals in 45 states and totals about 8 million records. This large database is an excellent representative sample of the general US population, representing > 95% of the US population, and is useful for analyzing healthcare utilization, access, charges, quality and outcomes [9,10]. The NIS database provides only administrative data for analysis.…”

Section: Methodsmentioning

confidence: 99%

Nationwide trends of hospital admissions for acute cholecystitis in the United States

Wadhwa

Jobanputra

Garg

et al. 2016

Gastroenterology Report

View full text Add to dashboard Cite

Background and aims: Acute cholecystitis is a fairly common inpatient diagnosis among the gastrointestinal disorders. The aim of this study was to use a national database of US hospitals to evaluate the incidence and costs of hospital admissions associated with acute cholecystitis.Method: We analyzed the National Inpatient Sample Database (NIS) for all patients in which acute cholecystitis (ICD-9 codes: 574.00, 574.01, 574.30, 574.31, 574.60, 574.61 or 575.0) was the principal discharge diagnosis from 1997 to 2012. The NIS is the largest all-payer inpatient database in the United States and contains data from approximately 8 million hospital stays each year. The statistical significance of the difference in the number of hospital discharges, lengths of stay and associated hospital costs over the study period was determined by using the Chi-square test for trends.Results: In 1997, there were 149 661 hospital admissions with a principal discharge diagnosis of acute cholecystitis, which increased to 215 995 in 2012 ( P < 0.001). The mean length of stay for acute cholecystitis decreased by 17% between 1997 and 2012 (i.e. from 4.7 days to 3.9 days; (P < 0.05). During the same time period, however, mean hospital charges have increased by 195.4 % from US$14 608 per patient in 1997 to US$43 152 per patient in 2012 ( P < 0.001).Conclusion: The number of inpatient discharges related to acute cholecystitis has increased significantly in the United States over the last 16 years, along with a great increase in the associated hospital charges. However, there has been a gradual decline in the mean length of stay. Inpatient costs associated with acute cholecystitis contribute significantly to the total healthcare bill. Further research on cost-effective evaluation and management of acute cholecystitis is required.

show abstract

“…This high prevalence is associated with annual direct and indirect costs of more than 20 billion USD/year in the USA, corresponding to 3.5 million physician visits annually, and is one of the leading causes of work absenteeism [2,3]. Despite the prevalence and impact of IBS in the community, its pathogenesis remains unclear, and the efficacy of treatments using pharmacological and probiotic approaches is modest, focusing mainly on abdominal pain and bloating, considered as the two dominant and most troublesome symptoms of IBS [4].…”

Section: Introductionmentioning

confidence: 99%

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

Chambrun

Neut

Chau

et al. 2015

Digestive and Liver Disease

120

View full text Add to dashboard Cite

show abstract

In‐patient discharge rates for the irritable bowel syndrome – an analysis of national trends in the United States from 1997 to 2010

Abstract: SUMMARY BackgroundIrritable bowel syndrome (IBS) is one of the most common out-patient diagnoses in primary care and gastroenterology. There are limited data on the rate and costs associated with in-patient discharges for IBS.

Cited by 15 publications

References 26 publications

Healthcare utilization and costs associated with gastroparesis

Healthcare utilization and costs associated with gastroparesis

Nationwide trends of hospital admissions for acute cholecystitis in the United States

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

Contact Info

Product

Resources

About